B7–H3 and c-MET in advanced prostate cancer: exploring possibilities of novel bi-specific drug development
In conclusion, B7-H3 is a promising drug developing target for PCa; however, c-MET may be limited by its low expression in tumor site while relative higher expression in peri-tumor site in PCa. Further investigation is warranted regarding bi-specific drugs for B7-H3 and another marker.
Authors
- Xuexue Xiao
- Wenjia Sun (ORCID: https://orcid.org/0000-0002-5067-3276)
- Weiying He (ORCID: https://orcid.org/0000-0003-0241-7056)
- Chunxia Ao
- Yanan Yang (ORCID: https://orcid.org/0000-0002-6332-5916)
- Yanggeling Zhang
- Luyao Zhang (ORCID: https://orcid.org/0009-0008-5258-1413)
- Huiyu Li (ORCID: https://orcid.org/0000-0002-1977-3981)
- Jincheng Wang (ORCID: https://orcid.org/0000-0002-9918-1563)
- Xiyuan Wang (ORCID: https://orcid.org/0000-0002-2639-076X)
- De Pei Wu
- Junqiu Yue (ORCID: https://orcid.org/0000-0002-1984-8445)
Institutions
- Simcere Pharmaceutical (China) (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1186/s40001-025-02729-7
- Citations
- 2
- Primary Topic
- Boron Compounds in Chemistry
- Type
- article
- Field-Weighted Citation Impact
- 2.72
Funders
- Wu Jieping Medical Foundation